Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.
Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
FEBS J. 2023 Aug;290(16):3946-3962. doi: 10.1111/febs.16600. Epub 2022 Sep 5.
CEMIP (cell migration-inducing protein), also known as KIAA1199 or HYBID, is a protein involved in the depolymerisation of hyaluronic acid (HA), a major glycosaminoglycan component of the extracellular matrix. CEMIP was originally described in patients affected by nonsyndromic hearing loss and has subsequently been shown to play a key role in tumour initiation and progression, as well as arthritis, atherosclerosis and idiopathic pulmonary fibrosis. Despite the vast literature associating CEMIP with these diseases, its biology remains elusive. The present review article summarises all the major scientific evidence regarding its structure, function, role and expression, and attempts to cast light on a protein that modulates EMT, fibrosis and tissue inflammation, an unmet key aspect in several inflammatory disease conditions.
CEMIP(细胞迁移诱导蛋白),也称为 KIAA1199 或 HYBID,是一种参与透明质酸(HA)解聚的蛋白质,HA 是细胞外基质的主要糖胺聚糖成分。CEMIP 最初在患有非综合征性听力损失的患者中被描述,随后被证明在肿瘤起始和进展以及关节炎、动脉粥样硬化和特发性肺纤维化中发挥关键作用。尽管有大量文献将 CEMIP 与这些疾病联系起来,但它的生物学特性仍不清楚。本文综述了所有关于其结构、功能、作用和表达的主要科学证据,并试图阐明一种调节 EMT、纤维化和组织炎症的蛋白质,这是几种炎症性疾病状态中未满足的关键方面。